

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5549396

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	ANTHONY QUINN	10/21/2011
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	SYNAGEVA BIOPHARMA CORP.	
<b>Street Address:</b>	128 SPRING STREET	
<b>City:</b>	LEXINGTON	
<b>State/Country:</b>	MASSACHUSETTS	
<b>Postal Code:</b>	02421	
<b>PROPERTY NUMBERS Total: 1</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	16190878	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(203)271-8366	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	475-230-3373	
<b>Email:</b>	patents@alexion.com	
<b>Correspondent Name:</b>	ALEXION PHARMACEUTICALS, INC.	
<b>Address Line 1:</b>	100 COLLEGE STREET	
<b>Address Line 4:</b>	NEW HAVEN, CONNECTICUT 06510	
<b>ATTORNEY DOCKET NUMBER:</b>	SYN080 US C5	
<b>NAME OF SUBMITTER:</b>	DARLENE SUAREZ	
<b>SIGNATURE:</b>	/Darlene Suarez/	
<b>DATE SIGNED:</b>	05/31/2019	
<b>Total Attachments: 2</b>		
source=080US_2011-10-21_Assignment inventor to Synageva#page1.tif		
source=080US_2011-10-21_Assignment inventor to Synageva#page2.tif		

## ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to the undersigned inventor: **Anthony QUINN**, hereby sells and assigns to **Synageva BioPharma Corp.**, a corporation formed under the laws of Delaware, whose mailing address is 128 Spring Street, Suite 520, Lexington, MA 02421 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **Methods for Treating Lysosomal Acid Lipase Deficiency in Patients** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of September 9, 2011 (also known as United States Application No. 13/229,558), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor hereby represents that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.


The undersigned inventor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventor hereby represents that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventor.

IN WITNESS WHEREOF, executed by the undersigned inventor on the date opposite his/her name.

Date: 10/21/2011

Signature of Inventor: \_\_\_\_\_

  
Anthony QUINN

1429328\_1.DOCX